Compare RVSB & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RVSB | BNTC |
|---|---|---|
| Founded | 1923 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.8M | 405.7M |
| IPO Year | 1993 | N/A |
| Metric | RVSB | BNTC |
|---|---|---|
| Price | $5.21 | $13.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $28.25 |
| AVG Volume (30 Days) | 46.3K | ★ 253.4K |
| Earning Date | 01-29-2026 | 02-13-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 361.12 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $52,756,000.00 | N/A |
| Revenue This Year | $10.25 | N/A |
| Revenue Next Year | $11.23 | N/A |
| P/E Ratio | $23.59 | ★ N/A |
| Revenue Growth | ★ 15.20 | N/A |
| 52 Week Low | $4.74 | $9.70 |
| 52 Week High | $6.59 | $17.15 |
| Indicator | RVSB | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 52.23 |
| Support Level | $5.01 | $10.99 |
| Resistance Level | $5.62 | $13.36 |
| Average True Range (ATR) | 0.16 | 0.93 |
| MACD | -0.03 | 0.15 |
| Stochastic Oscillator | 6.56 | 84.01 |
Riverview Bancorp Inc is an American savings and loan holding company. The company through its subsidiaries engages in the business of attracting deposits and puts it to use in its market area to originate commercial business. It is organized into two operating segments, Banking Operations performed by the bank and trust and Investment Services performed by the Trust company. The company products and services include checking, saving, money market, mortgage, home equity, consumer, online banking, cash management, and others.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.